Clinica Chimica Acta:采用高效液相色谱-质谱联用技术(LC-MS/MS)对四种免疫支持药物进行全血定量分析

2019-12-02 MedSci MedSci原创

与免疫分析相对有限的分析性能和交叉反应性相比,免疫测定法和液相色谱串联质谱法(LC-MS/MS)是两种主要的免疫抑制剂治疗性药物监测方法,因此,LC-MS/MS方法也被认为是金标准。但是,目前仍需要解决缺乏系统评价和标准化的问题。

免疫分析相对有限的分析性能和交叉反应性相比,免疫测定法和液相色谱串联质谱法(LC-MS/MS)是两种主要的免疫抑制剂治疗性药物监测方法,因此,LC-MS/MS方法也被认为是金标准。但是,目前仍需要解决缺乏系统评价和标准化的问题。

本研究采用一步法沉淀蛋白制备血样建立了测定环孢素A、西罗莫司、他克莫司和依维莫司的LC-MS/MS方法。根据标准指南对新开发的方法进行了系统的评价和验证。

根据该指南对四种免疫抑制剂在人全血中的定量方法进行了验证。环孢霉素A,西罗莫司,他克莫司,everolimus 测量区间的下限(LLMI)分比为5, 0.5, 0.5,0.5ng / mL。线性相关系数均为>0.999。内部标准归一化(is归一化)矩阵校正因子在0.88-1.17之间。四种免疫抑制剂的5个重复的平均加标回收率在87.4-109.6%之间。

本研究建立了一种液相色谱-质谱联用技术,该方法样品制备时间短,色谱分析时间短,更便于临床诊断

原始出处:

Zi-Shan GongZhong-Hao WuA high-throughput LC-MS/MS method for the quantification of four immunosu- ppressants drugs in whole blood

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1933372, encodeId=d99c19333e2cf, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Mar 04 11:59:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849809, encodeId=c7a918498097e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 21 07:59:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553374, encodeId=51e015533e49e, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Wed Dec 04 12:59:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1933372, encodeId=d99c19333e2cf, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Mar 04 11:59:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849809, encodeId=c7a918498097e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 21 07:59:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553374, encodeId=51e015533e49e, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Wed Dec 04 12:59:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2020-06-21 windight
  3. [GetPortalCommentsPageByObjectIdResponse(id=1933372, encodeId=d99c19333e2cf, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Mar 04 11:59:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849809, encodeId=c7a918498097e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 21 07:59:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553374, encodeId=51e015533e49e, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Wed Dec 04 12:59:00 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-04 jeanqiuqiu